Entia Biosciences Inc (ERGO) financial statements (2022 and earlier)
Company profile
| Business Address |
13565 SW TUALATIN-SHERWOOD RD. SHERWOOD, OR 97140 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| SIC | 2833 - Medicinal Chemicals and Botanical Products (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 76 | 24 | 99 | 37 | 13 | ||
| Cash and cash equivalents | 76 | 24 | 99 | 37 | 13 | ||
| Receivables | 8 | 7 | 244 | 11 | 62 | ||
| Inventory, net of allowances, customer advances and progress billings | 70 | 40 | 95 | 139 | 132 | ||
| Inventory | 70 | 40 | 95 | 139 | 132 | ||
| Prepaid expense | 81 | 57 | 46 | ✕ | |||
| Prepaid expense and other current assets | ✕ | ✕ | ✕ | 34 | 33 | ||
| Other undisclosed current assets | 4 | 4 | |||||
| Total current assets: | 234 | 128 | 485 | 225 | 244 | ||
| Noncurrent Assets | |||||||
| Inventory, Noncurrent | 55 | ||||||
| Property, plant and equipment | 18 | 33 | 43 | 62 | 36 | ||
| Intangible assets, net (including goodwill) | 187 | 233 | 343 | 343 | 183 | ||
| Intangible assets, net (excluding goodwill) | 187 | 233 | 343 | 343 | 183 | ||
| Total noncurrent assets: | 205 | 320 | 386 | 406 | 219 | ||
| TOTAL ASSETS: | 439 | 449 | 871 | 631 | 463 | ||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities, including: | 1,360 | 961 | 569 | 1,158 | 655 | ||
| Accrued liabilities | 707 | 365 | 173 | ||||
| Employee-related liabilities | 153 | ||||||
| Other undisclosed accounts payable and accrued liabilities | 653 | 595 | 243 | 1,158 | 655 | ||
| Debt | 132 | 97 | 51 | 26 | 25 | ||
| Deferred compensation liability | (52) | (86) | (183) | (395) | |||
| Due to related parties | 8 | 9 | |||||
| Other undisclosed current liabilities | 605 | 234 | 444 | 580 | 823 | ||
| Total current liabilities: | 2,106 | 1,240 | 987 | 1,581 | 1,109 | ||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation | 276 | 2 | |||||
| Long-term debt, excluding current maturities | 276 | ||||||
| Capital lease obligations | 2 | ||||||
| Liabilities, other than long-term debt | 24 | ||||||
| Due to related parties | 24 | ||||||
| Total noncurrent liabilities: | 300 | 2 | |||||
| Total liabilities: | 2,406 | 1,240 | 987 | 1,581 | 1,111 | ||
| Stockholders' equity | |||||||
| Stockholders' equity attributable to parent, including: | (1,967) | (791) | (117) | (950) | (648) | ||
| Preferred stock | 0 | 0 | 0 | 0 | 0 | ||
| Common stock | 28 | 28 | 16 | 8 | 7 | ||
| Common stock, share subscribed but unissued, subscriptions receivable | (49) | (49) | |||||
| Additional paid in capital | 12,487 | 12,309 | 10,771 | 7,794 | 5,116 | ||
| Deferred compensation equity | (9) | ||||||
| Accumulated deficit | (14,473) | (13,077) | (10,817) | (8,520) | (5,328) | ||
| Other undisclosed stockholders' equity attributable to parent | (52) | (86) | (183) | (395) | |||
| Total stockholders' equity: | (1,967) | (791) | (117) | (950) | (648) | ||
| TOTAL LIABILITIES AND EQUITY: | 439 | 449 | 871 | 631 | 463 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|
| Revenues | 265 | 347 | 656 | 315 | 369 | |
| Cost of revenue (Cost of Goods and Services Sold) | (91) | (131) | (280) | (163) | (134) | |
| Other undisclosed gross profit | 34 | 32 | 26 | |||
| Gross profit: | 174 | 216 | 411 | 184 | 262 | |
| Operating expenses | (1,484) | (2,242) | (2,209) | (3,154) | (1,342) | |
| Operating loss: | (1,310) | (2,026) | (1,798) | (2,970) | (1,081) | |
| Nonoperating income (expense) | (7) | (36) | 7 | 75 | 4 | |
| Investment income, nonoperating | 10 | 4 | ||||
| Debt instrument, convertible, beneficial conversion feature | 65 | |||||
| Other nonoperating income (expense) | (7) | (36) | 7 | |||
| Interest and debt expense | (79) | (175) | (337) | 75 | ||
| Net loss: | (1,396) | (2,237) | (2,127) | (2,895) | (1,001) | |
| Other undisclosed net loss attributable to parent | (23) | (169) | (210) | (263) | ||
| Net loss attributable to parent: | (1,396) | (2,260) | (2,297) | (3,105) | (1,264) | |
| Other undisclosed net income (loss) available to common stockholders, basic | (109) | 21 | ||||
| Net loss available to common stockholders, basic: | (1,396) | (2,260) | (2,297) | (3,214) | (1,243) | |
| Convertible preferred dividends | (88) | |||||
| Net loss available to common stockholders, diluted: | (1,396) | (2,260) | (2,297) | (3,301) | (1,243) | |
Comprehensive Income ($ in thousands)
| 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|
| Net loss: | (1,396) | (2,237) | (2,127) | (2,895) | (1,001) | |
| Comprehensive loss, net of tax, attributable to parent: | (1,396) | (2,237) | (2,127) | (2,895) | (1,001) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.